Osteotec entered an exclusive agreement to distribute Cerapedics’ i-FACTOR bone graft portfolio in the UK and Ireland.
This agreement provides healthcare professionals with access to Cerapedics’ i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR products for use in spine procedures.
The i-FACTOR portfolio is powered by the proprietary P-15 Osteogenic Cell Binding Peptide, which provides a mechanism of action to attach and activate osteogenic cells to accelerate new bone formation.
“This partnership is an important step in our global growth strategy,” said Stewart Jefferson, Cerapedics General Manager, International. “Osteotec’s established market presence and commitment to service excellence make them an ideal partner. Together, we are confident we can deliver effective solutions to surgeons while improving patient outcomes throughout the UK and Ireland.”
Source: Osteotec
Osteotec entered an exclusive agreement to distribute Cerapedics' i-FACTOR bone graft portfolio in the UK and Ireland.
This agreement provides healthcare professionals with access to Cerapedics' i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR products for use in spine procedures.
The i-FACTOR portfolio is powered by the...
Osteotec entered an exclusive agreement to distribute Cerapedics’ i-FACTOR bone graft portfolio in the UK and Ireland.
This agreement provides healthcare professionals with access to Cerapedics’ i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR products for use in spine procedures.
The i-FACTOR portfolio is powered by the proprietary P-15 Osteogenic Cell Binding Peptide, which provides a mechanism of action to attach and activate osteogenic cells to accelerate new bone formation.
“This partnership is an important step in our global growth strategy,” said Stewart Jefferson, Cerapedics General Manager, International. “Osteotec’s established market presence and commitment to service excellence make them an ideal partner. Together, we are confident we can deliver effective solutions to surgeons while improving patient outcomes throughout the UK and Ireland.”
Source: Osteotec
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.